[LCID Study Number: 20203176]

An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination With Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants With Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy

The purpose of this study is to compare the efficacy and safety of belzutifan and lenvatinib vs cabozantinib in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy.

Disease/Condition: Renal Cell Cancer

Department: Hematology and Oncology

Location(s): Lahey Hospital & Medical Center (Burlington); Lahey Medical Center, Peabody

Primary Contact Email: [email protected]

Primary Contact Phone: 781-744-3421